130 related articles for article (PubMed ID: 3152957)
1. Methotrexate concentration levels in the cerebrospinal fluid during high-dose methotrexate infusions: an unreliable prediction.
Lippens RJ; Winograd B
Pediatr Hematol Oncol; 1988; 5(2):115-24. PubMed ID: 3152957
[TBL] [Abstract][Full Text] [Related]
2. [Cerebrospinal fluid methotrexate level in children treated with medium-high and high doses of the drug].
Wysocki M; Balcar-Boroń A; Krzyzanowski M; Szadujkis-Szadurski L; Ozyński T; Nowaczyk-Michalak A
Acta Haematol Pol; 1992; 23(3):185-90. PubMed ID: 1492543
[TBL] [Abstract][Full Text] [Related]
3. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics of methotrexate in cerebrospinal fluid and serum after osmotic blood-brain barrier disruption in patients with brain lymphoma.
Zylber-Katz E; Gomori JM; Schwartz A; Lossos A; Bokstein F; Siegal T
Clin Pharmacol Ther; 2000 Jun; 67(6):631-41. PubMed ID: 10872645
[TBL] [Abstract][Full Text] [Related]
5. Variability in methotrexate serum and cerebrospinal fluid pharmacokinetics in children with acute lymphocytic leukemia: relation to assay methodology and physiological variables.
Seidel H; Andersen A; Kvaløy JT; Nygaard R; Moe PJ; Jacobsen G; Lindqvist B; Slørdal L
Leuk Res; 2000 Mar; 24(3):193-9. PubMed ID: 10739001
[TBL] [Abstract][Full Text] [Related]
6. [Investigation on individualized adjustment of target range of high-dose methotrexate].
Hua Y; Zhao WH; Lu XT; Yang LH; Lu W
Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):203-8. PubMed ID: 19099710
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate in the plasma and cerebrospinal fluid of children treated with intermediate dose methotrexate.
Rechnitzer C; Scheibel E; Hendel J
Acta Paediatr Scand; 1981 Sep; 70(5):615-8. PubMed ID: 6976674
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?
Niemann A; Mühlisch J; Frühwald MC; Gerss J; Hempel G; Boos J
Ther Drug Monit; 2010 Aug; 32(4):467-75. PubMed ID: 20571463
[TBL] [Abstract][Full Text] [Related]
9. Cerebrospinal fluid drug levels of leukemic children receiving intravenous 5 g/m2 methotrexate.
Millot F; Rubie H; Mazingue F; Mechinaud F; Thyss A
Leuk Lymphoma; 1994 Jun; 14(1-2):141-4. PubMed ID: 7920221
[TBL] [Abstract][Full Text] [Related]
10. Changes of cerebral biopterin and biogenic amine metabolism in leukemic children receiving 5 g/m2 intravenous methotrexate.
Millot F; Dhondt JL; Mazingue F; Mechinaud F; Ingrand P; Guilhot F
Pediatr Res; 1995 Feb; 37(2):151-4. PubMed ID: 7537364
[TBL] [Abstract][Full Text] [Related]
11. [Abnormally high methotrexate levels in the cerebrospinal fluid after intravenous and intrathecal treatment for acute lymphoblastic leukemia].
Négre V; Leneveu A; Chevallier B; Roux A
Arch Fr Pediatr; 1991 Jan; 48(1):63. PubMed ID: 2018429
[No Abstract] [Full Text] [Related]
12. Cerebrospinal fluid and plasma methotrexate levels following high-dose regimen given as a 3-hour intravenous infusion in children with nonHodgkin's lymphoma.
Vassal G; Valteau D; Bonnay M; Patte C; Aubier F; Lemerle J
Pediatr Hematol Oncol; 1990; 7(1):71-7. PubMed ID: 2397170
[TBL] [Abstract][Full Text] [Related]
13. Cerebrospinal fluid exchange after intrathecal methotrexate overdose. A report of two cases.
Jakobson AM; Kreuger A; Mortimer O; Henningsson S; Seidel H; Moe PJ
Acta Paediatr; 1992 Apr; 81(4):359-61. PubMed ID: 1606401
[TBL] [Abstract][Full Text] [Related]
14. [Effects of infusion duration of high-dose methotrexate on cerebrospinal fluid drug levels in lymphoma patients].
Lin XB; Zhou NN; Li S; Cai QQ; Xia ZJ; Liao H; Gao Y; Huang HQ
Ai Zheng; 2008 Oct; 27(10):1100-5. PubMed ID: 18851792
[TBL] [Abstract][Full Text] [Related]
15. Individualized methotrexate dosing in children with relapsed acute lymphoblastic leukemia.
Wall AM; Gajjar A; Link A; Mahmoud H; Pui CH; Relling MV
Leukemia; 2000 Feb; 14(2):221-5. PubMed ID: 10673736
[TBL] [Abstract][Full Text] [Related]
16. Randomized comparison of 36-hour intermediate-dose versus 4-hour high-dose methotrexate infusions for remission induction in relapsed childhood acute lymphoblastic leukemia.
Wolfrom C; Hartmann R; Fengler R; Brühmüller S; Ingwersen A; Henze G
J Clin Oncol; 1993 May; 11(5):827-33. PubMed ID: 8487046
[TBL] [Abstract][Full Text] [Related]
17. 7-Hydroxymethotrexate concentrations in serum and cerebrospinal fluid of children with acute lymphoblastic leukemia.
Borsi JD; Sagen E; Romslo I; Slørdal L; Moe PJ
Cancer Chemother Pharmacol; 1990; 27(2):164-7. PubMed ID: 2249335
[TBL] [Abstract][Full Text] [Related]
18. Methotrexate concentrations in cerebrospinal fluid and serum, and the risk of central nervous system relapse in children with acute lymphoblastic leukaemia.
Jönsson P; Höglund P; Wiebe T; Schrøder H; Seidel H; Skärby T
Anticancer Drugs; 2007 Sep; 18(8):941-8. PubMed ID: 17667600
[TBL] [Abstract][Full Text] [Related]
19. Methotrexate: distribution in cerebrospinal fluid after intravenous, ventricular and lumbar injections.
Shapiro WR; Young DF; Mehta BM
N Engl J Med; 1975 Jul; 293(4):161-6. PubMed ID: 806016
[TBL] [Abstract][Full Text] [Related]
20. Rapid infusion of high-dose methotrexate resulting in enhanced penetration into cerebrospinal fluid and intensified tumor response in primary central nervous system lymphomas.
Hiraga S; Arita N; Ohnishi T; Kohmura E; Yamamoto K; Oku Y; Taki T; Sato M; Aozasa K; Yoshimine T
J Neurosurg; 1999 Aug; 91(2):221-30. PubMed ID: 10433310
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
